$599

Novo Receives MHRA Approval of Wegovy Pill in the UK

Novo Nordisk announced it received MHRA approval of Wegovy Pill (25mg QD oral semaglutide) for adults with obesity and ≥1 weight-related condition. This approval is based on results from the Ph3 OASIS 4 trial (view publication). Below, FENIX provides brief thoughts on how the OUS Wegovy Pill expansion may impact Novo’s business trajectory.

This content is for Read Less members only.
Already a member? Log in here